Lipid-lowering therapies to target cardiac allograft vasculopathy after heart transplantation: Current evidence and future directions

Taha Mansoor; Mahmoud Ismayl; Salim S. Virani; Vijay Nambi; Arunima Misra; Xiaoming Jia; Marat Fudim; Stephen J. Greene; Laurence Sperling; Sachin Parikh; Mahmoud Al Rifai; Santhosh K.G. Koshy; Dmitry Abramov; Abdul Mannan Khan Minhas

doi:10.1016/j.jacl.2025.12.001

Lipid-lowering therapies to target cardiac allograft vasculopathy after heart transplantation: Current evidence and future directions

Taha Mansoor, Mahmoud Ismayl, Salim S. Virani, Vijay Nambi, Arunima Misra, Xiaoming Jia, Marat Fudim, Stephen J. Greene, Laurence Sperling, Sachin Parikh, Mahmoud Al Rifai, Santhosh K.G. Koshy, Dmitry Abramov, Abdul Mannan Khan Minhas

Research output: Contribution to journal › Review article › peer-review

Abstract

BACKGROUND Heart transplantation represents an increasingly utilized procedure for end-stage heart failure patients. CURRENT EVIDENCE Cardiac allograft vasculopathy (CAV) is a post-transplant complication of pathological vasculature remodeling and remains an important cause for long-term graft failure and mortality. Current preventive strategies for CAV include optimization of vascular risk factors and pharmacotherapy with statins and immunosuppressants. CONCLUSION Despite demonstrated post-transplant mortality benefit and reduction in CAV with statins, the role of other pharmacotherapies on CAV reduction through low-density lipoprotein cholesterol (LDL-C) lowering remains less established. This review explores established evidence as well as evolving pathways for LDL-C lowering strategies to prevent CAV.

Original language	English (US)
Pages (from-to)	262-269
Number of pages	8
Journal	Journal of Clinical Lipidology
Volume	20
Issue number	2
DOIs	https://doi.org/10.1016/j.jacl.2025.12.001
State	E-pub ahead of print - Dec 4 2025

Keywords

Cardiac allograft vasculopathy
Heart transplant
Pharmacotherapy

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Nutrition and Dietetics
Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jacl.2025.12.001

Cite this

Mansoor, T., Ismayl, M., Virani, S. S., Nambi, V., Misra, A., Jia, X., Fudim, M., Greene, S. J., Sperling, L., Parikh, S., Rifai, M. A., Koshy, S. K. G., Abramov, D., & Minhas, A. M. K. (2025). Lipid-lowering therapies to target cardiac allograft vasculopathy after heart transplantation: Current evidence and future directions. Journal of Clinical Lipidology, 20(2), 262-269. Advance online publication. https://doi.org/10.1016/j.jacl.2025.12.001

Mansoor, T, Ismayl, M, Virani, SS, Nambi, V, Misra, A, Jia, X, Fudim, M, Greene, SJ, Sperling, L, Parikh, S, Rifai, MA, Koshy, SKG, Abramov, D & Minhas, AMK 2025, 'Lipid-lowering therapies to target cardiac allograft vasculopathy after heart transplantation: Current evidence and future directions', Journal of Clinical Lipidology, vol. 20, no. 2, pp. 262-269. https://doi.org/10.1016/j.jacl.2025.12.001

@article{c720567caac6459daba7f57190efa2cf,

title = "Lipid-lowering therapies to target cardiac allograft vasculopathy after heart transplantation: Current evidence and future directions",

abstract = "BACKGROUND Heart transplantation represents an increasingly utilized procedure for end-stage heart failure patients. CURRENT EVIDENCE Cardiac allograft vasculopathy (CAV) is a post-transplant complication of pathological vasculature remodeling and remains an important cause for long-term graft failure and mortality. Current preventive strategies for CAV include optimization of vascular risk factors and pharmacotherapy with statins and immunosuppressants. CONCLUSION Despite demonstrated post-transplant mortality benefit and reduction in CAV with statins, the role of other pharmacotherapies on CAV reduction through low-density lipoprotein cholesterol (LDL-C) lowering remains less established. This review explores established evidence as well as evolving pathways for LDL-C lowering strategies to prevent CAV.",

keywords = "Cardiac allograft vasculopathy, Heart transplant, Pharmacotherapy",

author = "Taha Mansoor and Mahmoud Ismayl and Virani, \{Salim S.\} and Vijay Nambi and Arunima Misra and Xiaoming Jia and Marat Fudim and Greene, \{Stephen J.\} and Laurence Sperling and Sachin Parikh and Rifai, \{Mahmoud Al\} and Koshy, \{Santhosh K.G.\} and Dmitry Abramov and Minhas, \{Abdul Mannan Khan\}",

note = "Publisher Copyright: Copyright {\textcopyright} 2025. Published by Elsevier Inc.",

year = "2025",

month = dec,

day = "4",

doi = "10.1016/j.jacl.2025.12.001",

language = "English (US)",

volume = "20",

pages = "262--269",

journal = "Journal of Clinical Lipidology",

issn = "1933-2874",

publisher = "Elsevier Ltd",

number = "2",

}

TY - JOUR

T1 - Lipid-lowering therapies to target cardiac allograft vasculopathy after heart transplantation

T2 - Current evidence and future directions

AU - Mansoor, Taha

AU - Ismayl, Mahmoud

AU - Virani, Salim S.

AU - Nambi, Vijay

AU - Misra, Arunima

AU - Jia, Xiaoming

AU - Fudim, Marat

AU - Greene, Stephen J.

AU - Sperling, Laurence

AU - Parikh, Sachin

AU - Rifai, Mahmoud Al

AU - Koshy, Santhosh K.G.

AU - Abramov, Dmitry

AU - Minhas, Abdul Mannan Khan

PY - 2025/12/4

Y1 - 2025/12/4

N2 - BACKGROUND Heart transplantation represents an increasingly utilized procedure for end-stage heart failure patients. CURRENT EVIDENCE Cardiac allograft vasculopathy (CAV) is a post-transplant complication of pathological vasculature remodeling and remains an important cause for long-term graft failure and mortality. Current preventive strategies for CAV include optimization of vascular risk factors and pharmacotherapy with statins and immunosuppressants. CONCLUSION Despite demonstrated post-transplant mortality benefit and reduction in CAV with statins, the role of other pharmacotherapies on CAV reduction through low-density lipoprotein cholesterol (LDL-C) lowering remains less established. This review explores established evidence as well as evolving pathways for LDL-C lowering strategies to prevent CAV.

AB - BACKGROUND Heart transplantation represents an increasingly utilized procedure for end-stage heart failure patients. CURRENT EVIDENCE Cardiac allograft vasculopathy (CAV) is a post-transplant complication of pathological vasculature remodeling and remains an important cause for long-term graft failure and mortality. Current preventive strategies for CAV include optimization of vascular risk factors and pharmacotherapy with statins and immunosuppressants. CONCLUSION Despite demonstrated post-transplant mortality benefit and reduction in CAV with statins, the role of other pharmacotherapies on CAV reduction through low-density lipoprotein cholesterol (LDL-C) lowering remains less established. This review explores established evidence as well as evolving pathways for LDL-C lowering strategies to prevent CAV.

KW - Cardiac allograft vasculopathy

KW - Heart transplant

KW - Pharmacotherapy

UR - https://www.scopus.com/pages/publications/105026620529

UR - https://www.scopus.com/inward/citedby.url?scp=105026620529&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2025.12.001

DO - 10.1016/j.jacl.2025.12.001

M3 - Review article

AN - SCOPUS:105026620529

SN - 1933-2874

VL - 20

SP - 262

EP - 269

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

IS - 2

ER -

Lipid-lowering therapies to target cardiac allograft vasculopathy after heart transplantation: Current evidence and future directions

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this